Last reviewed · How we verify
NCT05463887: PDP
Personalized Disease Prevention
NA trial testing Individualized preventive care recommendations (decision tool) in Primary Prevention in 721 participants. Completed in 31 January 2026.
31 January 2026
Quick facts
| Lead sponsor | Glen Taksler |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 721 |
| Start date | 5 August 2022 |
| Primary completion | 31 January 2026 |
| Estimated completion | 31 January 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Individualized preventive care recommendations (decision tool)
Conditions studied
- Primary Prevention — all drugs for Primary Prevention →
- Healthy Aging — all drugs for Healthy Aging →
- Quality of Life — all drugs for Quality of Life →
- Decision Support Techniques — all drugs for Decision Support Techniques →
Sponsor
Glen Taksler
Who can join
Adults 40 to 75, any sex, with Primary Prevention or Healthy Aging. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate whether patients and their providers benefit from an evidence-based decision tool to help prioritize preventive (and select chronic disease management) services based on their potential to improve quality-adjusted life expectancy, individualized for patient risk factors. The study seeks to enroll 600 patients and 60 primary care providers. Half of providers will be assigned to an intervention to utilize the decision tool with approximately 10 high-priority patients each (patients of particular interest to the research study, on whom follow-up outcomes will be collected), and half will be assigned to usual care. Surveys will be administered at baseline and approximately 6 months later; electronic health records data on preventive service utilization will be collected; and optional qualitative interviews may be conducted.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Personalized Disease Prevention (PDP): study protocol for a cluster-randomized clinical trial.
Taksler GB, Le P, Hu B, Alberts J, et al · · 2022 · PMID 36273151 · DOI 10.1186/s13063-022-06750-7
Verify or expand the search:
- PubMed search for NCT05463887
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Primary Prevention
Currently open trials in the same condition.
- NCT06722521 — GUIDE-CAC: Statin-Ezetimibe Without Aspirin vs. Statin Monotherapy With Aspirin in High Coronary Calcification · Phase 4 · recruiting
- NCT06865885 — LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering · Phase 4 · recruiting
- NCT07045623 — Comparison of Intensive Versus Standard Care & Education for Dyslipidemia in Hypertension and Diabetes Patients · NA · recruiting
- NCT06615791 — FIT FIRST Teen - School Intervention Study · NA · recruiting
- NCT05993754 — Non-pharmacological Prevention of POD in Frailty Elderly Undergoing Elective Surgery Applied by Nursing Teams · NA · recruiting
Other Glen Taksler trials
Trials by the same sponsor.
- NCT03023813 — Individualizing Disease Prevention for Middle-Aged Adults · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05463887 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Glen Taksler
- Last refreshed: 2 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05463887.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing